NOT-DA-18-010: Notice of Intent to Publish a Funding Opportunity Announcement for the Reissue of PA-18-568 International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)

Notice of Intent to Publish a Funding Opportunity Announcement for the Reissue of PA-18-568 International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)

Notice Number: NOT-DA-18-010

Key Dates
Release Date: April 2, 2018
Estimated Publication Date of Announcement: 05/08/2018
First Estimated Application Due Date: 06/05/2018
Earliest Estimated Award Date: 11/01/2018
Earliest Estimated Start Date: 01/01/2019

Related Announcements
PA-18-773
PA-18-568

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to reissue PA-18-568, International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional) to solicit applications to encourage collaborative research applications on drug abuse and addiction.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in May 2018 with an expected application due date in June 2018.

This FOA will utilize the R01 activity code.

Details of the planned FOA are provided below.

Research Initiative Details

This Notice encourages investigators with expertise and insights in any area of NIDA-supported research and access to resources outside the United States to begin to consider applying for this new FOA.

Collaborative investigations combining expertise in the following areas will be particularly encouraged and these investigators should also begin considering applying for this application: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with comorbid disorders); the nature, extent, short- and long-term sequelae, prevention, and treatment of opioid overdoses and use of new psychoactive substances; the neuroscience of marijuana and cannabinoids; and the effects of changes in laws and policies on marijuana.

Among the areas of research encouraged in this initiative are basic research examining the mechanisms that underlie the effects of drug abuse and addiction, as well as research designed to improve the translation of existing knowledge of strategies for the prevention and treatment of drug abuse and addiction.

Funding Information

Estimated Total Funding

TBD

Expected Number of Awards

TBD

Estimated Award Ceiling

TBD

Primary CFDA Numbers

93.279

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
City or township governments
Special district governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Steven Gust, Ph.D.
National Institute on Drug Abuse (NIDA)
301-443-6480
ipdirector@nida.nih.gov

Steven Gust, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6480
Email: ipdirector@nida.nih.gov